Hostname: page-component-65b85459fc-cljkw Total loading time: 0 Render date: 2025-10-16T12:45:44.525Z Has data issue: false hasContentIssue false

Muting the self”: emotional dysregulation & appeareance and performance-enhancing drugs (APEDs); a clinical report

Published online by Cambridge University Press:  26 August 2025

G. García Cepero*
Affiliation:
Servicio de Psiquiatría, Hospital Universitario La Paz
M. E. Román Mazuecos
Affiliation:
Servicio de Psiquiatría, Hospital Universitario La Paz
M. A. Morillas Romerosa
Affiliation:
Centro de Salud Mental de Tetuán, Madrid, Spain
M. Velasco Santos
Affiliation:
Servicio de Psiquiatría, Hospital Universitario La Paz
I. D. De Juan
Affiliation:
Servicio de Psiquiatría, Hospital Universitario La Paz
P. Vázquez Giraldo
Affiliation:
Servicio de Psiquiatría, Hospital Universitario La Paz
H. Rincón Reques
Affiliation:
Servicio de Psiquiatría, Hospital Universitario La Paz
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Appearance and performance-enhancing drugs (APEDs) are a group of loosely-related substances that are used to improve characteristics perceived as desirable, such as external appearance, mental efficiency and sexual prowess. Besides the increasingly popular anabolic-androgenic steroids (AAS), there is an ever-growing array of anorectics, anabolism-enhancers, sedatives and nootropics available to the public.

Objectives

This case report aims to explore the connection between emotional dysregulation, self-actualization and side-effects that arise in users of these drugs.

Methods

We present the case of a 34-year-old male diagnosed with posttraumatic stress disorder and comorbid use of both anabolic-androgenic steroids (including testosterone, nandrolone and trenbolone) and chemsex-related substances (such as mephedrone, GHB and sildenafil). He reported frequent mood swings, constant feelings of loneliness and despair and occasional suicidal ideation; and attributed his pattern of substance abuse to a desire to escape from his “ordinary” self. After being admitted at a local emergency room during a suicidal crisis, he was referred to a mental health outpatient service and informed about the area’s addiction treatment resources. During the first outpatient interventions he related his symptoms (tachycardia, excessive sweating, restlessness, bursts of rage and paranoid reactions) to his pattern of APED consumption. He is currently undergoing both individual and group therapy in an MBT-based intervention; reports several months substance-free and has been started on a course of antidepressants (vortioxetine, up to 20 mg per day) and sedatives (zolpidem, 10 mg a day) to help him cope with his distress.

Results

Several authors have explored the relationship between personality and APED use. While some have found a correlation between the “dark triad traits” (mostly machiavellianism) and AAS consumption, others have noted the role these substances play in building up both identity and self-worth. According to Macho et al. (Front Psychol 2021; 12:648467) APEDs provide access to an “actualized” and “extraordinary” self that enables amateur athletes to escape both everyday life and previous trauma. This way out might be dangerous for the user’s health, but proves to be an enticing road, particularly to young males such as the one we present in this case.

Conclusions

APEDs are an increasingly popular group of substances, and they are going unnoticed in some clinical settings. Unlike other drugs, its use is not only recreational but directed to a specific goal; a quest for extraordinariness (in appearance, performance or prowess) that is deeply embedded in our culture. Having both a broad spectrum of physical side effects and a myriad of psychiatric implications, it is vital for mental health professionals to be familiar with this reality when assessing patients, particularly young men.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.